All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Adjuvant Ribociclib Revamps HR+/HER2– Breast Cancer Management

October 24th 2024

Jairam Krishnamurthy, MD, FACP, discusses factors that influence his choice between ribociclib and abemaciclib in the adjuvant breast cancer setting.

FDA Grants Priority Review to TLX101-CDx for Glioma Imaging

October 24th 2024

The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer

October 24th 2024

Pembrolizumab-based combinations have been approved in Europe in 2 new indications for endometrial and cervical cancer.

Fox Chase Cancer Center’s Dr. Allision Aggon Receives Earth Angel Award From Breast Cancer Nonprofit Organization

October 24th 2024

Allison A. Aggon, DO, FACOS, of Fox Chase Cancer Center, was recently presented with an Earth Angel Award.

The Escalating Need for Robust Decision Support in Oncology: Ovarian Cancer as an Example

October 24th 2024

The speed at which new drugs, combinations, and novel approaches are being introduced into routine practice presents a challenge for treating oncologists

Investigative Targeted Agents Are Set to Expand the BCG-Unresponsive NMIBC Treatment Paradigm

October 24th 2024

Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.

177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression

October 23rd 2024

177Lu-PNT2002 improved radiographic progression-free survival in PSMA-positive mCRPC after progression on an ARPI.

Telisotuzumab Adizutecan Delivers Early Signals of Antitumor Activity in CRC

October 23rd 2024

John H. Strickler, MD, discusses treatment with telisotuzumab adizutecan for CRC as well as this ADC’s potential to broaden the CRC treatment paradigm.

Cilta-cel Maintains Survival Benefit in Lenalidomide-Refractory Multiple Myeloma

October 23rd 2024

Binod Dhakal, MD, MS, discusses updated survival data from the CARTITUDE-4 trial of cilta-cel in pretreated, lenalidomide-refractory multiple myeloma.

Adolescents/Young Adults With Cancer Experience Increased Financial Toxicity, Unmet Social Needs

October 23rd 2024

Routine screening revealed high financial toxicity and unmet social needs among adolescent and young adults with cancer.

SC Daratumumab Plus VRd Earns EU Approval in Newly Diagnosed, Transplant-Eligible Myeloma

October 23rd 2024

The European Commission has approved daratumumab plus bortezomib, lenalidomide, and dexamethasone in ASCT-eligible, newly diagnosed multiple myeloma.

Fadraciclib Demonstrates Safety, Early Efficacy Signals in CDKN2A/B+ Advanced Solid Tumors

October 23rd 2024

Fadraciclib was safe and showed signs of efficacy in advanced solid tumors harboring CDKN2A/B alterations.

ADCs Redefine HER2+ NSCLC Landscape With Potential to Shift to the Frontline Setting

October 23rd 2024

Noman Ashraf, MD, discusses data with T-DXd in HER2-mutated and -overexpressing lung cancer populations and next steps with ADC combination therapies.

Clinical Trial Education Is Essential in Hematology and Oncology Fellowship Curricula

October 23rd 2024

Many early-career clinicians are not familiarized with clinical trials during their training, so the opportunity to educate future trialists is hindered.

First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma

October 23rd 2024

Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

October 22nd 2024

Treatment with the BTK degrader NX-5948 led to responses in patients with relapsed/refractory Waldenström macroglobulinemia.

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer

October 22nd 2024

The FDA has approved the Ventana CLDN18 (43-14A) RxDx Assay as a companion diagnostic for zolbetuximab in CLDN18.2-positive gastric/GEJ cancer.

Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML

October 22nd 2024

Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

October 22nd 2024

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

ONCT-534 Reduces PSA Levels, Is Tolerable in Relapsed/Refractory mCRPC

October 22nd 2024

ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.